Malaysia aims 100 cybersecurity experts accredited as C-CISO this year
He said that through the C-CISO Certification Programme, the ministry is committed to producing more talents and experts in the field, to strengthen the public sector's preparedness against cyber threats.
The initiative, he said, was implemented through a strategic collaboration with the EC-Council and the Human Resource Development Corporation (HRD Corp), with the first seven participants receiving the certification today.
'Our target is that by the end of this year, we can produce a total of 100 C-CISOs as a start and moving forward, we want to see more people showing interest and participating in this programme,' he told a press conference after launching the Cyber Security Professional Capability Development Programme here today.
He said the programme would also be expanded to other sectors to ensure local talents in the field of cybersecurity could continue to be polished and developed continuously.
Also present were the Digital Ministry secretary-general Fabian Bigar, CyberSecurity Malaysia chief executive officer Datuk Dr Amirudin Abdul Wahab and EC-Council president Sanjay Bavisi.
Earlier in his speech, Gobind Singh said the certification program is one of the key components in supporting the implementation of the Cyber Security Act 2024 (Act 854), especially among National Critical Infrastructure (NCII) entities.
'As a Chief Information Security Officer (CISO), the person holds a strategic role in ensuring the organisation's compliance with the provisions under Act 854.
'The responsibilities of the CISO include formulating cybersecurity policies, implementing technical controls, risk management and organisational preparedness in dealing with cyber incidents, in addition to serving as a strategic link between the government, industry, technology providers and the NCII community,' he said.
He said a CISO also plays a crucial role in shaping and driving a security-first culture within an organisation by promoting continuous training and certification, while ensuring that all systems and technologies in use adhere to established security standards.
The C-CISO programme covers five main domains, including governance, security audit, data protection, operations management and strategic planning, which Gobind described as a long-term investment in the development of the country's digital leadership.
'If in the past, the strength of a country was measured through the military, today it depends on the security and trust in digital systems. Digital defence is the main pillar of the country's prosperity and stability,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
ONEMAIN HOLDINGS, INC. REPORTS SECOND QUARTER 2025 RESULTS
2Q 2025 Diluted EPS of $1.40 2Q 2025 C&I adjusted diluted EPS of $1.45 2Q 2025 Managed receivables of $25.2 billion Declared quarterly dividend of $1.04 per share NEW YORK, July 25, 2025 /PRNewswire/ — OneMain Holdings, Inc. (NYSE: OMF), the leader in offering nonprime consumers responsible access to credit, today reported pretax income of $214 million and net income of $167 million for the second quarter of 2025, compared to $92 million and $71 million, respectively, in the prior year quarter. Earnings per diluted share were $1.40 in the second quarter of 2025, compared to $0.59 in the prior year quarter. On July 25, 2025, OneMain declared a quarterly dividend of $1.04 per share, payable on August 13, 2025, to record holders of the Company's common stock as of the close of business on August 4, 2025. During the quarter, the Company repurchased approximately 460 thousand shares of common stock for $21 million. 'OneMain's strong financial results in the first half of 2025 reflect the strength of our business model and our disciplined approach to underwriting,' said Doug Shulman, Chairman and CEO of OneMain. 'With solid growth in high-quality originations, continued credit improvement, disciplined balance sheet management and execution of our strategic initiatives, we continue to create shareholder value.' The following segment results are reported on a non-GAAP basis. Refer to the required reconciliations of non-GAAP to comparable GAAP measures at the end of this press release. Consumer and Insurance Segment ('C&I') C&I adjusted pretax income was $231 million and adjusted net income was $173 million for the second quarter of 2025, compared to $163 million and $122 million, respectively, in the prior year quarter. Adjusted earnings per diluted share were $1.45 for the second quarter of 2025, compared to $1.02 in the prior year quarter. Management runs the business based on capital generation, which it defines as C&I adjusted net income excluding the after-tax change in C&I allowance for finance receivable losses while still considering the current period C&I net charge-offs. Capital generation was $222 million for the second quarter 2025, compared to $136 million in the prior year quarter. The increase was driven by receivable growth and improved credit performance in the current quarter compared to the prior year period. Managed receivables, which includes loans serviced for our whole loan sale partners and auto finance loans originated by third parties, were $25.2 billion at June 30, 2025, up 7% from $23.7 billion at June 30, 2024. Consumer loan originations totaled $3.9 billion in the second quarter of 2025, up 9% from $3.6 billion in the prior year quarter. Total revenue, comprising interest income and total other revenue, was $1.5 billion in the second quarter of 2025, up 10% from $1.4 billion in the prior year quarter. Interest income in the second quarter of 2025 was $1.3 billion, up 10% from $1.2 billion in the prior year quarter. The increase was driven by receivable growth and improved portfolio yield. Interest expense was $317 million in the second quarter of 2025, up 7% from $295 million in the prior year quarter, due to an increase in average debt to support our receivables growth and a higher average cost of funds. The provision for finance receivable losses was $511 million in the second quarter of 2025, down $4 million compared to the prior year period. During the second quarter of 2025, the allowance for finance receivable losses increased $65 million driven by growth in receivables. C&I Select Delinquency and Loss Ratios June 30, 2025 March 31, 2025 June 30, 2024 Consumer loans: 30+ days delinquency ratio 5.17 % 5.16 % 5.45 % 90+ days delinquency ratio 2.12 % 2.38 % 2.33 % 30-89 days delinquency ratio 3.05 % 2.77 % 3.13 % Net charge-offs 7.19 % 7.83 % 8.29 % Operating expense for the second quarter of 2025 was $415 million, up 11% from $374 million in the prior year quarter reflecting receivable growth and our strategic investments in the business. Funding and Liquidity As of June 30, 2025, the Company had principal debt balances outstanding of $22.4 billion, 57% of which was secured. The Company had $769 million of cash and cash equivalents, which included $185 million of cash and cash equivalents held at regulated insurance subsidiaries or for other operating activities that are unavailable for general corporate purposes. Cash and cash equivalents, together with the Company's $1.1 billion of undrawn committed capacity from an unsecured corporate revolver, $6.4 billion of undrawn committed capacity under revolving conduit facilities and credit card variable funding note facilities, and $9.7 billion of unencumbered receivables, provides significant liquidity resources. Conference Call & Webcast Information OneMain management will host a conference call and webcast to discuss the Company's results, outlook, and related matters at 9:00 am Eastern Time on Friday, July 25, 2025. Both the call and webcast are open to the general public. The general public is invited to listen to the call by dialing 800-579-2568 (U.S. domestic) or 785-424-1222 (international), and using conference ID 67083, or via a live audio webcast through OneMain's investor relations website at For those unable to listen to the live broadcast, a replay will be available on the website after the event. An investor presentation will be available on the OneMain's investor relations website prior to the start of the conference call. About OneMain Holdings, Inc. OneMain Financial (NYSE: OMF) is the leader in offering nonprime consumers responsible access to credit and is dedicated to improving the financial well-being of hardworking Americans. We empower our customers to solve today's problems and reach a better financial future through personalized solutions across 47 states, available online and in 1,300 locations. OneMain is committed to making a positive impact on the people and the communities we serve. For additional information, please visit Use of Non-GAAP Financial Measures We report the operating results of Consumer and Insurance using the Segment Accounting Basis, which (i) reflects our allocation methodologies for interest expense and operating costs, to reflect the manner in which we assess our business results and (ii) excludes the impact of applying purchase accounting (eliminates premiums/discounts on our finance receivables and long-term debt at acquisition, as well as the amortization/accretion in future periods). Consumer and Insurance adjusted pretax income (loss), Consumer and Insurance adjusted net income (loss), and Consumer and Insurance adjusted earnings (loss) per diluted share are key performance measures used to evaluate the performance of our business. Consumer and Insurance adjusted pretax income (loss) represents income (loss) before income taxes on a Segment Accounting Basis and excludes net loss resulting from repurchases and repayments of debt, restructuring charges, acquisition-related transaction and integration expenses, regulatory settlements, and strategic activities and other items. We believe these non-GAAP financial measures are useful in assessing the profitability of our segment. We also use pretax capital generation and capital generation, non-GAAP financial measures, as a key performance measure of our segment. Pretax capital generation represents Consumer and Insurance adjusted pretax income, as discussed above, and excludes the change in our Consumer and Insurance allowance for finance receivable losses in the period while still considering the Consumer and Insurance net charge-offs incurred during the period. Capital generation represents the after-tax effect of pretax capital generation. We believe that these non-GAAP measures are useful in assessing the capital created in the period impacting the overall capital adequacy of the Company. We believe that the Company's reserves, combined with its equity, represent the Company's loss absorption capacity. We utilize these non-GAAP measures in evaluating our performance. Additionally, these non-GAAP measures are consistent with the performance goals established in OMH's executive compensation program. These non-GAAP financial measures should be considered supplemental to, but not as a substitute for or superior to, income (loss) before income taxes, net income, or other measures of financial performance prepared in accordance with GAAP. This document contains summarized information concerning the Company and its business, operations, financial performance and trends. No representation is made that the information in this document is complete. For additional financial, statistical and business related information see the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the 'SEC'), as well as the Company's other reports filed with the SEC from time to time, which are or will be available in the Investor Relations section of the OneMain Financial website ( and the SEC's website ( Cautionary Note Regarding Forward-Looking StatementsThis document contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words 'anticipates,' 'appears,' 'assumes,' 'believes,' 'can,' 'continues,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'foresees,' 'goal,' 'intends,' 'likely,' 'objective,' 'plans,' 'projects,' 'target,' 'trend,' 'remains,' and similar expressions or future or conditional verbs such as 'could,' 'may,' 'might,' 'should,' 'will' or 'would' are intended to identify forward-looking statements, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements are not statements of historical fact but instead represent only management's current beliefs regarding future events, objectives, goals, projections, strategies, performance, and future plans, and underlying assumptions and other statements related thereto. You should not place undue reliance on these forward-looking statements. By their nature, forward-looking statements are subject to risks, uncertainties, assumptions and other important factors that may cause actual results, performance or achievements to differ materially from those expressed in or implied by such forward-looking statements. Important factors that could cause actual results, performance, or achievements to differ materially from those expressed in or implied by forward-looking statements include, without limitation, the following: adverse changes and volatility in general economic conditions, including the interest rate environment and the financial markets; the sufficiency of our allowance for finance receivable losses; increased levels of unemployment and personal bankruptcies; the current inflationary environment and related trends affecting our customers; natural or accidental events such as earthquakes, hurricanes, pandemics, floods or wildfires affecting our customers, collateral, or our facilities; a failure in or breach of our information, operational or security systems or infrastructure or those of third parties, including as a result of cyber incidents, war or other disruptions; the adequacy of our credit risk scoring models; geopolitical risks, including recent geopolitical actions outside the U.S.; adverse changes in our ability to attract and retain employees or key executives; increased competition or adverse changes in customer responsiveness to our distribution channels or products; changes in federal, state, or local laws, regulations, or regulatory policies and practices or increased regulatory scrutiny of our business or industry; risks associated with our insurance operations; the costs and effects of any actual or alleged violations of any federal, state, or local laws, rules or regulations; the costs and effects of any fines, penalties, judgments, decrees, orders, inquiries, investigations, subpoenas, or enforcement or other proceedings of any governmental or quasi-governmental agency or authority; our substantial indebtedness and our continued ability to access the capital markets and maintain adequate current sources of funds to satisfy our cash flow requirements; our ability to comply with all of our covenants; the effects of any downgrade of our debt ratings by credit rating agencies; and other risks and uncertainties described in the 'Risk Factors' and 'Management's Discussion and Analysis' sections of the Company's most recent Form 10-K filed with the SEC and in the Company's other filings with the SEC from time to time. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, our actual results may vary materially from what we may have expressed or implied by these forward-looking statements. You should specifically consider the factors identified in this document that could cause actual results to differ before making an investment decision to purchase our securities. Furthermore, new risks and uncertainties arise from time to time, and it is impossible for us to predict those events or how they may affect us. Forward looking statements included in this document speak only as of the date on which they were made. We undertake no obligation to update or revise any forward-looking statements, whether written or oral, to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events or the non-occurrence of anticipated events, whether as a result of new information, future developments or otherwise, except as required by law. OneMain Holdings, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Quarter Ended Fiscal Year (unaudited, $ in millions, except per share amounts) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Interest income $ 1,339 $ 1,308 $ 1,320 $ 1,282 $ 1,219 $ 4,993 $ 4,564 Interest expense (317) (312) (311) (301) (297) (1,185) (1,019) Net interest income 1,022 996 1,009 981 922 3,808 3,545 Provision for finance receivable losses (511) (456) (523) (512) (575) (2,040) (1,721) Net interest income after provision for finance receivable losses 511 540 486 469 347 1,768 1,824 Insurance 111 110 111 111 111 445 448 Investment 24 26 21 24 30 108 116 Gain on sales of finance receivables 17 16 5 6 6 23 52 Net loss on repurchases and repayments of debt (21) (5) (19) (1) (12) (34) — Other 45 41 42 42 39 153 119 Total other revenues 176 188 160 182 174 695 735 Operating expenses (419) (404) (433) (401) (382) (1,607) (1,530) Insurance policy benefits and claims (54) (49) (49) (43) (47) (189) (189) Total other expenses (473) (453) (482) (444) (429) (1,796) (1,719) Income before income taxes 214 275 164 207 92 667 840 Income taxes (47) (62) (38) (50) (21) (158) (199) Net income $ 167 $ 213 $ 126 $ 157 $ 71 $ 509 $ 641 Weighted average number of diluted shares 119.4 120.0 119.9 120.1 120.2 120.1 120.6 Diluted EPS $ 1.40 $ 1.78 $ 1.05 $ 1.31 $ 0.59 $ 4.24 $ 5.32 Book value per basic share $ 27.99 $ 27.50 $ 26.74 $ 26.87 $ 26.33 $ 26.74 $ 26.60 Return on assets 2.5 % 3.3 % 1.9 % 2.5 % 1.1 % 2.0 % 2.7 % Change in allowance for finance receivable losses $ (66) $ 17 $ (60) $ (81) $ (79) $ (194) $ (185) Net charge-offs (445) (473) (463) (431) (496) (1,846) (1,536) Provision for finance receivable losses $ (511) $ (456) $ (523) $ (512) $ (575) $ (2,040) $ (1,721) Note: Quarters may not sum to fiscal year due to rounding. OneMain Holdings, Inc. CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of (unaudited, $ in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 Assets Cash and cash equivalents $ 769 $ 627 $ 458 $ 577 $ 667 Investment securities 1,683 1,670 1,607 1,581 1,681 Net finance receivables 23,870 23,328 23,554 23,075 22,365 Unearned insurance premium and claim reserves (764) (747) (766) (765) (753) Allowance for finance receivable losses (2,754) (2,688) (2,705) (2,645) (2,564) Net finance receivables, less unearned insurance premium and claim reserves and allowance for finance receivable losses 20,352 19,893 20,083 19,665 19,048 Restricted cash and restricted cash equivalents 742 736 684 693 630 Goodwill 1,474 1,474 1,474 1,474 1,474 Other intangible assets 285 285 286 288 289 Other assets 1,323 1,344 1,318 1,300 1,296 Total assets $ 26,628 $ 26,029 $ 25,910 $ 25,578 $ 25,085 Liabilities and Shareholders' Equity Long-term debt $ 22,053 $ 21,494 $ 21,438 $ 21,137 $ 20,671 Insurance claims and policyholder liabilities 579 567 575 597 594 Deferred and accrued taxes 18 19 20 29 10 Other liabilities 652 669 686 607 657 Total liabilities 23,302 22,749 22,719 22,370 21,932 Common stock 1 1 1 1 1 Additional paid-in capital 1,745 1,734 1,734 1,728 1,723 Accumulated other comprehensive loss (51) (65) (81) (59) (95) Retained earnings 2,425 2,384 2,296 2,295 2,263 Treasury stock (794) (774) (759) (757) (739) Total shareholders' equity 3,326 3,280 3,191 3,208 3,153 Total liabilities and shareholders' equity $ 26,628 $ 26,029 $ 25,910 $ 25,578 $ 25,085 OneMain Holdings, Inc. CONSOLIDATED KEY FINANCIAL METRICS (UNAUDITED) As of (unaudited, $ in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 Liquidity Cash and cash equivalents $ 769 $ 627 $ 458 $ 577 $ 667 Cash and cash equivalents unavailable for general corporate purposes 185 139 123 266 211 Unencumbered receivables 9,709 10,163 9,738 9,017 8,060 Undrawn conduit facilities 5,999 5,999 5,999 6,749 6,399 Undrawn corporate revolver 1,125 1,125 1,125 1,125 1,325 Private secured term funding available — 725 — — — Undrawn credit card revolving variable funding note facilities 400 400 300 300 300 Drawn conduit facilities 1 1 1 176 1 Net adjusted debt $ 21,297 $ 20,833 $ 20,931 $ 20,653 $ 20,043 Total Shareholders' equity $ 3,326 $ 3,280 $ 3,191 $ 3,208 $ 3,153 Accumulated other comprehensive loss 51 65 81 59 95 Goodwill (1,474) (1,474) (1,474) (1,474) (1,474) Other intangible assets (285) (285) (286) (288) (289) Junior subordinated debt 172 172 172 172 172 Adjusted tangible common equity 1,790 1,758 1,684 1,677 1,657 Allowance for finance receivable losses, net of tax * 2,065 2,016 2,029 1,984 1,923 Adjusted capital $ 3,855 $ 3,774 $ 3,713 $ 3,661 $ 3,580 Net leverage (net adjusted debt to adjusted capital) 5.5x 5.5x 5.6x 5.6x 5.6x * Income taxes assume a 25% tax rate. OneMain Holdings, Inc. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (UNAUDITED) Quarter Ended Fiscal Year (unaudited, $ in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Consumer & Insurance $ 211 $ 270 $ 159 $ 200 $ 145 $ 707 $ 845 Other (1) 1 (1) — — (1) (6) Segment to GAAP adjustment 4 4 6 7 (53) (39) 1 Income before income taxes – GAAP basis $ 214 $ 275 $ 164 $ 207 $ 92 $ 667 $ 840 Consumer & Insurance pretax income $ 211 $ 270 $ 159 $ 200 $ 145 $ 707 $ 845 Net loss on repurchases and repayments of debt 20 5 19 — 12 33 — Restructuring charges — — 1 1 — 29 — Acquisition-related transaction and integration expenses — — 5 1 2 9 — Regulatory settlements — — — — — — 26 Other (1) — — 1 — 4 4 3 Consumer & Insurance adjusted pretax income (non-GAAP) $ 231 $ 275 $ 185 $ 202 $ 163 $ 782 $ 874 Reconciling items (2) $ (16) $ (1) $ (20) $ 5 $ (71) $ (114) $ (28) Consumer & Insurance $ 23,901 $ 23,365 $ 23,598 $ 23,128 $ 22,428 $ 23,598 $ 21,349 Segment to GAAP adjustment (31) (37) (44) (53) (63) (44) — Net finance receivables – GAAP basis $ 23,870 $ 23,328 $ 23,554 $ 23,075 $ 22,365 $ 23,554 $ 21,349 Consumer & Insurance $ 2,758 $ 2,693 $ 2,710 $ 2,651 $ 2,571 $ 2,710 $ 2,480 Segment to GAAP adjustment (4) (5) (5) (6) (7) (5) — Allowance for finance receivable losses – GAAP basis $ 2,754 $ 2,688 $ 2,705 $ 2,645 $ 2,564 $ 2,705 $ 2,480 Note: Quarters may not sum to fiscal year due to rounding. (1) Includes strategic activities and other items. (2) Reconciling items consist of Segment to GAAP adjustment and the adjustments to Pretax income – segment accounting basis for C&I and Other. The adjustments to Other adjusted pretax income (loss) are not disclosed in the table above due to immateriality. OneMain Holdings, Inc. CONSUMER & INSURANCE SEGMENT (UNAUDITED) (Non-GAAP) Quarter Ended Fiscal Year (unaudited, in millions, except per share amounts) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Interest income $ 1,333 $ 1,301 $ 1,312 $ 1,271 $ 1,210 $ 4,965 $ 4,559 Interest expense (317) (311) (310) (299) (295) (1,181) (1,015) Net interest income 1,016 990 1,002 972 915 3,784 3,544 Provision for finance receivable losses (511) (456) (523) (512) (515) (1,981) (1,721) Net interest income after provision for finance receivable losses 505 534 479 460 400 1,803 1,823 Insurance 111 110 111 111 111 445 448 Investment 24 26 21 24 30 108 116 Gain on sales of finance receivables 17 16 5 6 6 23 52 Other 43 39 40 40 37 146 111 Total other revenues 195 191 177 181 184 722 727 Operating expenses (415) (401) (422) (396) (374) (1,554) (1,487) Insurance policy benefits and claims (54) (49) (49) (43) (47) (189) (189) Total other expenses (469) (450) (471) (439) (421) (1,743) (1,676) Adjusted pretax income (non-GAAP) 231 275 185 202 163 782 874 Income taxes * (58) (68) (46) (51) (41) (195) (219) Adjusted net income (non-GAAP) $ 173 $ 207 $ 139 $ 151 $ 122 $ 587 $ 655 Weighted average number of diluted shares 119.4 120.0 119.9 120.1 120.2 120.1 120.6 C&I adjusted diluted EPS $ 1.45 $ 1.72 $ 1.16 $ 1.26 $ 1.02 $ 4.89 $ 5.43 Note: Quarters may not sum to fiscal year due to rounding. * Income taxes assume a 25% tax rate. OneMain Holdings, Inc. CONSUMER & INSURANCE SEGMENT METRICS (UNAUDITED) Quarter Ended Fiscal Year (unaudited, $ in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Net finance receivables – personal loans $ 20,814 $ 20,469 $ 20,833 $ 20,569 $ 20,073 $ 20,833 $ 20,274 Net finance receivables – auto finance 2,335 2,220 2,122 2,009 1,889 2,122 745 Net finance receivables – consumer loans 23,149 22,689 22,955 22,578 21,962 22,955 21,019 Net finance receivables – credit cards 752 676 643 550 466 643 330 Net finance receivables $ 23,901 $ 23,365 $ 23,598 $ 23,128 $ 22,428 $ 23,598 $ 21,349 Allowance for finance receivable losses $ 2,758 $ 2,693 $ 2,710 $ 2,651 $ 2,571 $ 2,710 $ 2,480 Allowance ratio 11.54 % 11.52 % 11.48 % 11.46 % 11.46 % 11.48 % 11.62 % Net finance receivables 23,901 23,365 23,598 23,128 22,428 23,598 21,349 Finance receivables serviced for our whole loan sale partners 1,316 1,232 1,141 1,191 1,229 1,141 882 Managed receivables $ 25,217 $ 24,597 $ 24,739 $ 24,319 $ 23,657 $ 24,739 $ 22,231 Average net finance receivables – personal loans $ 20,637 $ 20,660 $ 20,751 $ 20,396 $ 19,937 $ 20,301 $ 19,788 Average net finance receivables – auto finance 2,278 2,166 2,072 1,949 1,843 1,662 559 Average net finance receivables – consumer loans 22,915 22,826 22,823 22,345 21,780 21,963 20,347 Average net finance receivables – credit cards 719 668 599 515 430 477 181 Average net receivables 23,634 23,494 23,422 22,860 22,210 22,440 20,528 Average receivables serviced for our whole loan sale partners 1,285 1,196 1,174 1,218 1,195 1,113 852 Average managed receivables $ 24,919 $ 24,690 $ 24,596 $ 24,078 $ 23,405 $ 23,553 $ 21,380 OneMain Holdings, Inc. CONSUMER & INSURANCE KEY METRICS (UNAUDITED) (Non-GAAP) Quarter Ended Fiscal Year (unaudited, in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Adjusted pretax income (non-GAAP) $ 231 $ 275 $ 185 $ 202 $ 163 $ 782 $ 874 Provision for finance receivable losses 511 456 523 512 515 1,981 1,721 Net charge-offs (446) (473) (464) (432) (496) (1,849) (1,536) Change in C&I allowance for finance receivable losses (non-GAAP) 65 (17) 59 80 19 132 185 Pretax capital generation (non-GAAP) 296 258 244 282 182 914 1,059 Capital generation, net of tax* (non-GAAP) $ 222 $ 194 $ 183 $ 211 $ 136 $ 685 $ 794 C&I average net receivables $ 23,634 $ 23,494 $ 23,422 $ 22,860 $ 22,210 $ 22,440 $ 20,528 Capital generation return on receivables (non-GAAP) 3.8 % 3.3 % 3.1 % 3.7 % 2.9 % 3.1 % 3.9 % Note: Consumer & Insurance financial information is presented on an adjusted Segment Accounting Basis. Amounts may not sum to fiscal year due to rounding. * Income taxes assume a 25% rate. OneMain Holdings, Inc. CONSUMER & INSURANCE CONSUMER LOANS METRICS (UNAUDITED) Quarter Ended Fiscal Year (unaudited, $ in millions) Jun 30,2025 Mar 31,2025 Dec 31,2024 Sep 30,2024 Jun 30,2024 2024 2023 Gross charge-offs $ 496 $ 525 $ 514 $ 490 $ 553 $ 2,080 $ 1,768 Recoveries (85) (85) (76) (78) (75) (307) (258) Net charge-offs $ 411 $ 440 $ 438 $ 412 $ 478 $ 1,773 $ 1,510 Gross charge-off ratio 8.68 % 9.34 % 8.96 % 8.72 % 9.68 % 9.34 % 8.69 % Recovery ratio (1.49 %) (1.52 %) (1.33 %) (1.39 %) (1.39 %) (1.39 %) (1.27 %) Net charge-off ratio 7.19 % 7.83 % 7.63 % 7.33 % 8.29 % 7.94 % 7.42 % Average net receivables $ 22,915 $ 22,826 $ 22,823 $ 22,345 $ 21,780 $ 21,963 $ 20,346 Yield 22.6 % 22.4 % 22.2 % 22.1 % 21.9 % 22.1 % 22.2 % Origination volume $ 3,907 $ 3,022 $ 3,504 $ 3,712 $ 3,582 $ 13,321 $ 12,851 30+ delinquency $ 1,197 $ 1,170 $ 1,322 $ 1,272 $ 1,198 $ 1,322 $ 1,294 90+ delinquency $ 491 $ 540 $ 579 $ 562 $ 511 $ 579 $ 605 30-89 delinquency $ 706 $ 630 $ 743 $ 710 $ 687 $ 743 $ 689 30+ delinquency ratio 5.17 % 5.16 % 5.76 % 5.63 % 5.45 % 5.76 % 6.16 % 90+ delinquency ratio 2.12 % 2.38 % 2.52 % 2.49 % 2.33 % 2.52 % 2.88 % 30-89 delinquency ratio 3.05 % 2.77 % 3.24 % 3.14 % 3.13 % 3.24 % 3.28 % Note: Consumer & Insurance financial information is presented on a Segment Accounting Basis. Delinquency ratios are calculated as a percentage of C&I consumer loan net finance receivables. Amounts may not sum due to rounding. Defined Terms Adjusted capital: adjusted tangible common equity + allowance for finance receivable losses (ALLL), net of tax Adjusted tangible common equity (TCE): total shareholders' equity – accumulated other comprehensive loss – goodwill – other intangible assets + junior subordinated debt Auto finance: financing at the point of purchase through a network of auto dealerships Available cash and cash equivalents: cash and cash equivalents – cash and cash equivalents held at our regulated insurance subsidiaries or is unavailable for general corporate purposes Average assets: average of monthly average assets (assets at the beginning and end of each month divided by two) in the period Average managed receivables: C&I average net receivables + average receivables serviced for our whole loan sale partners C&I adjusted diluted EPS: C&I adjusted net income (non-GAAP) / weighted average diluted shares Capital generation: C&I adjusted net income – change in C&I allowance for finance receivable losses, net of tax Capital generation return on receivables*: annualized capital generation / C&I average net receivables Consumer loans: personal loans and auto finance Finance receivables serviced for our whole loan sale partners: unpaid principal balance plus accrued interest of loans sold as part of our whole loan sale program Gross charge-off ratio*: annualized gross charge-offs / average net receivables Managed receivables: C&I net finance receivables + finance receivables serviced for our whole loan sale partners + auto finance loans originated by third parties Net adjusted debt: long-term debt – junior subordinated debt – available cash and cash equivalents Net charge-off ratio*: annualized net charge-offs / average net receivables Net leverage: net adjusted debt / adjusted capital Opex ratio: annualized C&I operating expenses / average managed receivables Origination volume: loans originated during the period, including those originated and sold to our whole loan sale partners that we continue to service Other net revenue: other revenues – insurance policy benefits and claims expense Personal loans: loans secured by titled collateral or unsecured and offered through our branch network, central operations, or digital platform Pretax capital generation: C&I pretax adjusted net income – change in C&I allowance for finance receivable losses Purchase volume: credit card purchase transactions + cash advances – returns Return on assets (ROA): annualized net income / average total assets Return on receivables (C&I ROR): annualized C&I adjusted net income / C&I average net receivables Total revenue: C&I interest income + C&I total other revenue Unencumbered receivables: unencumbered unpaid principal balance of consumer loans and credit cards. For precompute personal loans, unpaid principal balance is the gross contractual payments less the unaccreted balance of unearned finance charges. Credit card receivables include those in the trust that exceed the minimum for securing advances under credit card variable funding note facilities, which the Company can remove from the trust under the terms of such facilities, and exclude billed interest, fees, and closed accounts with balances * 2Q24 and fiscal year 2024 adjusted for policy alignment associated with the Foursight acquisition. OneMain Holdings, Inc. Investor Contact:Peter R. Poillon, Media Contact:Kelly Ogburn,
The Star
a day ago
- The Star
Vietnam to buy two Lockheed Martin helicopters, sources say, as US trade talks carry on
File photo of people visiting a Lockheed Martin booth displaying a model of a military transport plane during an arms fair, in Hanoi, Vietnam in December 2024. - Reuters HANOI: Vietnam's police ministry has agreed to buy two Lockheed Martin helicopters, according to three people with knowledge of the talks, in what would be a key security deal since Washington lifted an arms embargo on the Communist-run nation a decade ago. The deal would come after the country's ministry of public security held protracted talks since at least 2022 with multiple US defence companies to acquire helicopters. Lockheed Martin is also negotiating with Vietnam's defence ministry the sale of C-130 military transport planes, multiple officials have said. Vietnam, which relies heavily on Russian weapons, has been looking for years to diversify its arsenal. It is also currently negotiating with the Trump administration key elements of a tariff deal that is crucial to maintain access to its largest export market. Vietnamese pilots have already been training with Lockheed Martin's Sikorsky helicopters, one of the sources with direct knowledge said, noting the deal was worth more than US$100 million and could include more choppers at a later stage. The source did not specify the chopper model under discussion but said pilots were training with S-92 helicopters, which are employed in several countries for both civilian and military uses. Another two sources briefed on the talks confirmed Vietnam had agreed to buy two Lockheed Martin helicopters but gave no information about the cost and the model. All sources declined to be named because the information was not public. Reuters could not establish when the deal could be completed and whether there were contractual aspects to be defined. Since an arms embargo on Vietnam was lifted in 2016, US security deals with its former foe have been limited to coastguard ships and trainer aircraft, which could lead to the procurement of military planes. Lockheed Martin said queries on procurement should be directed to the Vietnamese government. Calls to Vietnam's ministry of public security went unanswered. The foreign ministry did not reply to a request for comment. Vietnam's parliament approved in June 2022 the establishment of a mobile police unit to tackle crime, terrorism and riots, which would need helicopters to operate, according to the government and the text of the 2022 legislation. US officials have said Washington sees Vietnam as a key player on regional security and would be willing to boost Vietnam's defence, especially in the South China Sea, where it is often at odds with China over disputed boundaries. Support for the police could be more controversial. The latest US State Department's report on human rights in Vietnam, released in 2023, warned of significant violations and abuses by security forces. Vietnam's foreign ministry has said the report was biased and inaccurate. The sources did not explicitly link the possible procurement deal to tariff talks, but Vietnamese and US officials have repeatedly said purchases of US military equipment would strengthen Hanoi's position in negotiating a fully-fledged trade agreement. US President Donald Trump announced earlier in July a deal on 20% tariffs for Vietnamese goods imported into the United States, 40% levies on transshipped products and no duties for US exports to Vietnam. However, Hanoi has instead talked of a preliminary framework agreement. Talks are still underway to finalise the agreement. - Reuters
Malaysian Reserve
2 days ago
- Malaysian Reserve
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO, July 23, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. 'This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma,' said Dr. Helen Torley, President and CEO of Halozyme. 'We are pleased that the new treatment paradigm addresses the critical needs of people living with this complex blood disease.' SMM is an asymptomatic intermediate disease state of multiple myeloma where abnormal cells can be detected in the bone marrow. The current standard of care for SMM, even in high-risk cases, is active monitoring (or 'Watch and Wait') to track for signs of biochemical progression and/or end-organ damage. This means therapeutic intervention is only offered when the disease progresses. The EC approval is supported by data from the Phase 3 AQUILA study (NCT03301220), evaluating the efficacy and safety of fixed-duration monotherapy daratumumab SC compared with active monitoring in those with high-risk SMM. For more information on the study and its findings, please view Johnson & Johnson's press release issued on July 23, 2025. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney
